Ask AI
ProCE Banner Activity

Experts Discuss Novel RAS-Targeted Therapy for Pancreatic Cancer

Podcast Episodes

Listen to Nilofer Azad, MD, FASCO, and Zev A. Wainberg, MD, as they discuss novel RAS-targeted therapies for pancreatic cancer, including optimal KRAS mutation testing, emerging multiselective RAS inhibitors, and combination strategies.

Released: February 24, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Revolution Medicines, Inc.

Revolution Medicines, Inc.

Target Audience

This educational activity is intended for oncologists and other healthcare professionals who care for patients with pancreatic cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply molecular profiling to identify actionable RAS(ON) alterations in patients with advanced pancreatic ductal adenocarcinoma (PDAC)

  • Analyze clinical data from key trials evaluating emerging RAS-targeted agents for metastatic PDAC

  • Refer eligible patients with PDAC to clinical trials of investigational RAS(ON)–targeted agents

Disclosure

Primary Author

Nilofer Azad, MD, FASCO: consultant/advisor/speaker: AstraZeneca, Bristol Myers Squibb, RevMed.

Zev A. Wainberg, MD: consultant/advisor/speaker: Alligator, Amgen, Arcus, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Ipsen, Janssen, Lilly, Merck, Novartis, Pfizer, Rev Med.